The GSK3 hypothesis of Alzheimer's disease.

PubWeight™: 3.16‹?› | Rank: Top 1%

🔗 View Article (PMC 3073119)

Published in J Neurochem on December 18, 2007

Authors

Claudie Hooper1, Richard Killick, Simon Lovestone

Author Affiliations

1: King's College London, MRC Centre for Neurodegenerative Research, Institute of Psychiatry, De Crespigny Park, Denmark Hill, London, UK.

Articles citing this

(truncated to the top 100)

Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline. J Clin Invest (2012) 3.65

Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci (2011) 2.96

Functional genomic screen and network analysis reveal novel modifiers of tauopathy dissociated from tau phosphorylation. Hum Mol Genet (2011) 1.72

HDAC6 regulates mitochondrial transport in hippocampal neurons. PLoS One (2010) 1.63

Alzheimer's disease-like pathological features in transgenic mice expressing the APP intracellular domain. Proc Natl Acad Sci U S A (2009) 1.57

Therapeutic potential of mood stabilizers lithium and valproic acid: beyond bipolar disorder. Pharmacol Rev (2013) 1.52

GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS. Front Mol Neurosci (2011) 1.47

Targeting protein kinases in central nervous system disorders. Nat Rev Drug Discov (2009) 1.45

Leptin regulates tau phosphorylation and amyloid through AMPK in neuronal cells. Biochem Biophys Res Commun (2009) 1.45

Chronic Microdose Lithium Treatment Prevented Memory Loss and Neurohistopathological Changes in a Transgenic Mouse Model of Alzheimer's Disease. PLoS One (2015) 1.42

PGC-1alpha in aging and anti-aging interventions. Biochim Biophys Acta (2009) 1.35

Functional genomic analyses identify pathways dysregulated by progranulin deficiency, implicating Wnt signaling. Neuron (2011) 1.34

Dynamin I phosphorylation by GSK3 controls activity-dependent bulk endocytosis of synaptic vesicles. Nat Neurosci (2010) 1.33

Phosphorylation-dependent regulation of PSF by GSK3 controls CD45 alternative splicing. Mol Cell (2010) 1.30

Chemical modulation of memory formation in larval zebrafish. Proc Natl Acad Sci U S A (2011) 1.27

The intersection of genetic and chemical genomic screens identifies GSK-3α as a target in human acute myeloid leukemia. J Clin Invest (2012) 1.24

ER-mitochondria associations are regulated by the VAPB-PTPIP51 interaction and are disrupted by ALS/FTD-associated TDP-43. Nat Commun (2014) 1.24

A pivotal role of GSK-3 in synaptic plasticity. Front Mol Neurosci (2012) 1.23

Deconstructing GSK-3: The Fine Regulation of Its Activity. Int J Alzheimers Dis (2011) 1.22

Diet-induced hyperhomocysteinemia increases amyloid-beta formation and deposition in a mouse model of Alzheimer's disease. Curr Alzheimer Res (2010) 1.18

Abnormal neuronal networks and seizure susceptibility in mice overexpressing the APP intracellular domain. Neurobiol Aging (2009) 1.16

Protein phosphorylation in neurodegeneration: friend or foe? Front Mol Neurosci (2014) 1.15

Natural products as a source of Alzheimer's drug leads. Nat Prod Rep (2010) 1.13

Marked calpastatin (CAST) depletion in Alzheimer's disease accelerates cytoskeleton disruption and neurodegeneration: neuroprotection by CAST overexpression. J Neurosci (2008) 1.13

A look inside the diabetic brain: Contributors to diabetes-induced brain aging. Biochim Biophys Acta (2008) 1.12

Leptin reduces the accumulation of Abeta and phosphorylated tau induced by 27-hydroxycholesterol in rabbit organotypic slices. J Alzheimers Dis (2010) 1.10

Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies. J Biol Chem (2012) 1.08

The frontotemporal dementia mutation R406W blocks tau's interaction with the membrane in an annexin A2-dependent manner. J Cell Biol (2011) 1.08

WNT signaling in activated microglia is proinflammatory. Glia (2010) 1.07

Combination therapy targeting Akt and mammalian target of rapamycin improves functional outcome after controlled cortical impact in mice. J Cereb Blood Flow Metab (2011) 1.06

Interaction between pathogenic proteins in neurodegenerative disorders. J Cell Mol Med (2012) 1.06

Tetrahydrohyperforin prevents cognitive deficit, Aβ deposition, tau phosphorylation and synaptotoxicity in the APPswe/PSEN1ΔE9 model of Alzheimer's disease: a possible effect on APP processing. Transl Psychiatry (2011) 1.04

Glucagon-like peptide-1 cleavage product GLP-1(9-36) amide rescues synaptic plasticity and memory deficits in Alzheimer's disease model mice. J Neurosci (2012) 1.04

Activation of glycogen synthase kinase-3 beta mediates β-amyloid induced neuritic damage in Alzheimer's disease. Neurobiol Dis (2011) 1.04

Genome-wide analysis of a Wnt1-regulated transcriptional network implicates neurodegenerative pathways. Sci Signal (2011) 1.03

Novel GαS-protein signaling associated with membrane-tethered amyloid precursor protein intracellular domain. J Neurosci (2012) 1.02

Leptin inhibits glycogen synthase kinase-3beta to prevent tau phosphorylation in neuronal cells. Neurosci Lett (2009) 1.02

Soluble 3',6-substituted indirubins with enhanced selectivity toward glycogen synthase kinase -3 alter circadian period. J Med Chem (2008) 1.01

Hyperphosphorylation of Tau induced by naturally secreted amyloid-β at nanomolar concentrations is modulated by insulin-dependent Akt-GSK3β signaling pathway. J Biol Chem (2012) 1.00

Small-Molecule Inhibitors of GSK-3: Structural Insights and Their Application to Alzheimer's Disease Models. Int J Alzheimers Dis (2012) 0.99

Tau, prions and Aβ: the triad of neurodegeneration. Acta Neuropathol (2010) 0.99

Neuroprotective effects of lithium: implications for the treatment of Alzheimer's disease and related neurodegenerative disorders. ACS Chem Neurosci (2014) 0.98

Amyloid β: linking synaptic plasticity failure to memory disruption in Alzheimer's disease. J Neurochem (2011) 0.98

GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cells. ACS Chem Biol (2013) 0.97

Evidence for irreversible inhibition of glycogen synthase kinase-3β by tideglusib. J Biol Chem (2011) 0.97

Deficiency in LRP6-mediated Wnt signaling contributes to synaptic abnormalities and amyloid pathology in Alzheimer's disease. Neuron (2014) 0.97

Linking tumor mutations to drug responses via a quantitative chemical-genetic interaction map. Cancer Discov (2014) 0.96

Glycogen synthase kinase 3 inhibition promotes adult hippocampal neurogenesis in vitro and in vivo. ACS Chem Neurosci (2012) 0.96

Lithium and neuroprotection: translational evidence and implications for the treatment of neuropsychiatric disorders. Neuropsychiatr Dis Treat (2013) 0.95

BioModels: Content, Features, Functionality, and Use. CPT Pharmacometrics Syst Pharmacol (2015) 0.94

Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment. Int J Alzheimers Dis (2011) 0.94

Insulin deficiency exacerbates cerebral amyloidosis and behavioral deficits in an Alzheimer transgenic mouse model. Mol Neurodegener (2010) 0.94

Linking cardiometabolic disorders to sporadic Alzheimer's disease: a perspective on potential mechanisms and mediators. J Neurochem (2010) 0.94

GSK3 Function in the Brain during Development, Neuronal Plasticity, and Neurodegeneration. Int J Alzheimers Dis (2011) 0.94

GSK3beta-mediated Drp1 phosphorylation induced elongated mitochondrial morphology against oxidative stress. PLoS One (2012) 0.93

NFAT/Fas signaling mediates the neuronal apoptosis and motor side effects of GSK-3 inhibition in a mouse model of lithium therapy. J Clin Invest (2010) 0.92

Different effects of soluble and aggregated amyloid β42 on gene/protein expression and enzyme activity involved in insulin and APP pathways. J Neural Transm (Vienna) (2012) 0.91

Modelling the role of the Hsp70/Hsp90 system in the maintenance of protein homeostasis. PLoS One (2011) 0.91

Wnts in action: from synapse formation to synaptic maintenance. Front Cell Neurosci (2013) 0.90

Desmin modifications associate with amyloid-like oligomers deposition in heart failure. Cardiovasc Res (2014) 0.90

Behavioral deficit, oxidative stress, and mitochondrial dysfunction precede tau pathology in P301S transgenic mice. FASEB J (2011) 0.90

Circadian rhythmicity of active GSK3 isoforms modulates molecular clock gene rhythms in the suprachiasmatic nucleus. J Biol Rhythms (2015) 0.90

Lithium reduces BACE1 overexpression, β amyloid accumulation, and spatial learning deficits in mice with traumatic brain injury. J Neurotrauma (2012) 0.90

Regulation by glycogen synthase kinase-3 of inflammation and T cells in CNS diseases. Front Mol Neurosci (2011) 0.90

Alzheimer disease therapeutics: focus on the disease and not just plaques and tangles. Biochem Pharmacol (2014) 0.90

Synthesis and evaluation of [(11)C]PyrATP-1, a novel radiotracer for PET imaging of glycogen synthase kinase-3β (GSK-3β). Nucl Med Biol (2014) 0.90

CDK5 activator protein p25 preferentially binds and activates GSK3β. Proc Natl Acad Sci U S A (2014) 0.89

Interaction between α-synuclein and other proteins in neurodegenerative disorders. ScientificWorldJournal (2011) 0.89

Histamine H3 receptor antagonists/inverse agonists on cognitive and motor processes: relevance to Alzheimer's disease, ADHD, schizophrenia, and drug abuse. Front Syst Neurosci (2012) 0.89

LRRK2 functions as a Wnt signaling scaffold, bridging cytosolic proteins and membrane-localized LRP6. Hum Mol Genet (2012) 0.89

Increased tau phosphorylation and impaired brain insulin/IGF signaling in mice fed a high fat/high cholesterol diet. J Alzheimers Dis (2013) 0.89

Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. Free Radic Biol Med (2013) 0.89

Glycogen synthase kinase 3 β activity is required for hBora/Aurora A-mediated mitotic entry. Cell Cycle (2013) 0.89

Inhibition of AMPA receptor trafficking at hippocampal synapses by beta-amyloid oligomers: the mitochondrial contribution. Mol Brain (2010) 0.88

Leptin signaling and Alzheimer's disease. Am J Neurodegener Dis (2012) 0.88

GSK-3 Mouse Models to Study Neuronal Apoptosis and Neurodegeneration. Front Mol Neurosci (2011) 0.88

Blockade of Tau hyperphosphorylation and Aβ₁₋₄₂ generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ₁ receptor agonist, in a nontransgenic mouse model of Alzheimer's disease. Neuropsychopharmacology (2013) 0.88

The nature, significance, and glucagon-like peptide-1 analog treatment of brain insulin resistance in Alzheimer's disease. Alzheimers Dement (2014) 0.88

Wnts in adult brain: from synaptic plasticity to cognitive deficiencies. Front Cell Neurosci (2013) 0.88

A new avenue for lithium: intervention in traumatic brain injury. ACS Chem Neurosci (2014) 0.88

Wnt3a induces exosome secretion from primary cultured rat microglia. BMC Neurosci (2012) 0.87

Adaptive cellular stress pathways as therapeutic targets of dietary phytochemicals: focus on the nervous system. Pharmacol Rev (2014) 0.87

A common pathogenic mechanism linking type-2 diabetes and Alzheimer's disease: evidence from animal models. J Clin Neurol (2011) 0.87

PET amyloid-beta imaging in preclinical Alzheimer's disease. Biochim Biophys Acta (2011) 0.87

Human isoprenoid synthase enzymes as therapeutic targets. Front Chem (2014) 0.86

Intranasal deferoxamine improves performance in radial arm water maze, stabilizes HIF-1α, and phosphorylates GSK3β in P301L tau transgenic mice. Exp Brain Res (2012) 0.86

GSK3 and p53 - is there a link in Alzheimer's disease? Mol Neurodegener (2010) 0.86

The role and therapeutic targeting of α-, β- and γ-secretase in Alzheimer's disease. Future Sci OA (2015) 0.86

Control of neuronal ion channel function by glycogen synthase kinase-3: new prospective for an old kinase. Front Mol Neurosci (2012) 0.86

Accelerating neuronal aging in in vitro model brain disorders: a focus on reactive oxygen species. Front Aging Neurosci (2014) 0.86

APP Receptor? To Be or Not To Be. Trends Pharmacol Sci (2016) 0.85

Amyloid-β oligomers induce tau-independent disruption of BDNF axonal transport via calcineurin activation in cultured hippocampal neurons. Mol Biol Cell (2013) 0.85

Altered regulation of tau phosphorylation in a mouse model of down syndrome aging. Neurobiol Aging (2011) 0.85

Phospholipid transfer protein reduces phosphorylation of tau in human neuronal cells. J Neurosci Res (2009) 0.85

Mild chronic cerebral hypoperfusion induces neurovascular dysfunction, triggering peripheral beta-amyloid brain entry and aggregation. Acta Neuropathol Commun (2013) 0.84

Glycogen Synthase Kinase-3 (GSK-3)-Targeted Therapy and Imaging. Theranostics (2016) 0.84

Synthesis and Initial in Vivo Studies with [(11)C]SB-216763: The First Radiolabeled Brain Penetrative Inhibitor of GSK-3. ACS Med Chem Lett (2015) 0.84

Neurofibrillary tangles and the deposition of a beta amyloid peptide with a novel N-terminal epitope in the brains of wild Tsushima leopard cats. PLoS One (2012) 0.84

Dynamic range of GSK3α not GSK3β is essential for bidirectional synaptic plasticity at hippocampal CA3-CA1 synapses. Hippocampus (2014) 0.83

Morin attenuates tau hyperphosphorylation by inhibiting GSK3β. Neurobiol Dis (2011) 0.83

Articles cited by this

Insulin signalling and the regulation of glucose and lipid metabolism. Nature (2001) 16.41

GSK-3: tricks of the trade for a multi-tasking kinase. J Cell Sci (2003) 10.89

Binding of GSK3beta to the APC-beta-catenin complex and regulation of complex assembly. Science (1996) 9.12

Requirement for glycogen synthase kinase-3beta in cell survival and NF-kappaB activation. Nature (2000) 8.37

GAB2 alleles modify Alzheimer's risk in APOE epsilon4 carriers. Neuron (2007) 6.88

Incipient Alzheimer's disease: microarray correlation analyses reveal major transcriptional and tumor suppressor responses. Proc Natl Acad Sci U S A (2004) 5.65

Wnt signaling in disease and in development. Cell Res (2005) 5.53

GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature (2003) 4.97

Functional redundancy of GSK-3alpha and GSK-3beta in Wnt/beta-catenin signaling shown by using an allelic series of embryonic stem cell lines. Dev Cell (2007) 4.39

Intranasal insulin improves cognition and modulates beta-amyloid in early AD. Neurology (2007) 4.14

Decreased nuclear beta-catenin, tau hyperphosphorylation and neurodegeneration in GSK-3beta conditional transgenic mice. EMBO J (2001) 3.22

LTP inhibits LTD in the hippocampus via regulation of GSK3beta. Neuron (2007) 3.17

Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem Res (2006) 3.12

Glycogen synthase kinase-3 is rapidly inactivated in response to insulin and phosphorylates eukaryotic initiation factor eIF-2B. Biochem J (1993) 2.98

Inhibition of glycogen synthase kinase-3 by lithium correlates with reduced tauopathy and degeneration in vivo. Proc Natl Acad Sci U S A (2005) 2.95

Glycogen synthase kinase-3 induces Alzheimer's disease-like phosphorylation of tau: generation of paired helical filament epitopes and neuronal localisation of the kinase. Neurosci Lett (1992) 2.85

A hundred years of Alzheimer's disease research. Neuron (2006) 2.76

Signal transduction by the Wnt family of ligands. Biochem J (1998) 2.66

Regulation and localization of tyrosine216 phosphorylation of glycogen synthase kinase-3beta in cellular and animal models of neuronal degeneration. Proc Natl Acad Sci U S A (2000) 2.34

The Wnt signalling pathway. J Cell Sci (2002) 2.20

Glycogen synthase kinase 3alpha-specific regulation of murine hepatic glycogen metabolism. Cell Metab (2007) 2.12

Association of microglia with amyloid plaques in brains of APP23 transgenic mice. Am J Pathol (1999) 2.10

Distribution of active glycogen synthase kinase 3beta (GSK-3beta) in brains staged for Alzheimer disease neurofibrillary changes. J Neuropathol Exp Neurol (1999) 2.08

Activity-dependent synaptic Wnt release regulates hippocampal long term potentiation. J Biol Chem (2006) 1.98

Tau protein kinase I is essential for amyloid beta-protein-induced neurotoxicity. Proc Natl Acad Sci U S A (1993) 1.92

GSK-3 phosphorylation of the Alzheimer epitope within collapsin response mediator proteins regulates axon elongation in primary neurons. J Biol Chem (2004) 1.91

Proapoptotic stimuli induce nuclear accumulation of glycogen synthase kinase-3 beta. J Biol Chem (2001) 1.90

PS1 activates PI3K thus inhibiting GSK-3 activity and tau overphosphorylation: effects of FAD mutations. EMBO J (2004) 1.89

Phosphatidylinositol 3-kinase is required for the expression but not for the induction or the maintenance of long-term potentiation in the hippocampal CA1 region. J Neurosci (2002) 1.85

Common genetic variation within the low-density lipoprotein receptor-related protein 6 and late-onset Alzheimer's disease. Proc Natl Acad Sci U S A (2007) 1.84

Alzheimer's disease-like phosphorylation of the microtubule-associated protein tau by glycogen synthase kinase-3 in transfected mammalian cells. Curr Biol (1994) 1.80

GSK-3beta inhibition reverses axonal transport defects and behavioural phenotypes in Drosophila. Mol Psychiatry (2004) 1.79

Presenilin 1 associates with glycogen synthase kinase-3beta and its substrate tau. Proc Natl Acad Sci U S A (1998) 1.71

Induction of Dickkopf-1, a negative modulator of the Wnt pathway, is associated with neuronal degeneration in Alzheimer's brain. J Neurosci (2004) 1.66

Neuroprotective effects of regulators of the glycogen synthase kinase-3beta signaling pathway in a transgenic model of Alzheimer's disease are associated with reduced amyloid precursor protein phosphorylation. J Neurosci (2007) 1.65

Distribution, levels, and activity of glycogen synthase kinase-3 in the Alzheimer disease brain. J Neuropathol Exp Neurol (1997) 1.63

Glycogen synthase kinase 3beta phosphorylates tau at both primed and unprimed sites. Differential impact on microtubule binding. J Biol Chem (2002) 1.62

Insulin-degrading enzyme as a downstream target of insulin receptor signaling cascade: implications for Alzheimer's disease intervention. J Neurosci (2004) 1.62

Increased risk of Alzheimer's disease in Type II diabetes: insulin resistance of the brain or insulin-induced amyloid pathology? Biochem Soc Trans (2005) 1.59

The insulin signalling pathway. Curr Biol (2002) 1.58

Insulin transiently increases tau phosphorylation: involvement of glycogen synthase kinase-3beta and Fyn tyrosine kinase. J Neurochem (1999) 1.52

Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci (2007) 1.50

Increased level of active GSK-3beta in Alzheimer's disease and accumulation in argyrophilic grains and in neurones at different stages of neurofibrillary degeneration. Neuropathol Appl Neurobiol (2007) 1.50

Phosphorylation of the cAMP response element binding protein CREB by cAMP-dependent protein kinase A and glycogen synthase kinase-3 alters DNA-binding affinity, conformation, and increases net charge. Biochemistry (1998) 1.45

Alternative splicing isoform of tau protein kinase I/glycogen synthase kinase 3beta. J Neurochem (2002) 1.45

Regulation of mitochondrial pyruvate dehydrogenase activity by tau protein kinase I/glycogen synthase kinase 3beta in brain. Proc Natl Acad Sci U S A (1996) 1.45

Preferential labeling of Alzheimer neurofibrillary tangles with antisera for tau protein kinase (TPK) I/glycogen synthase kinase-3 beta and cyclin-dependent kinase 5, a component of TPK II. Acta Neuropathol (1996) 1.44

Alzheimer vaccine: amyloid-beta on trial. Bioessays (2003) 1.43

Spatial learning deficit in transgenic mice that conditionally over-express GSK-3beta in the brain but do not form tau filaments. J Neurochem (2002) 1.42

Exposure of rat hippocampal neurons to amyloid beta peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen synthase kinase-3 beta. Neurosci Lett (1996) 1.40

Physiology and pathology of tau protein kinases in relation to Alzheimer's disease. J Biochem (1997) 1.37

Immune reactive cells in senile plaques and cognitive decline in Alzheimer's disease. Neurobiol Aging (2002) 1.36

GSK-3 mediates differentiation and activation of proinflammatory dendritic cells. Blood (2006) 1.34

Chronic lithium administration to FTDP-17 tau and GSK-3beta overexpressing mice prevents tau hyperphosphorylation and neurofibrillary tangle formation, but pre-formed neurofibrillary tangles do not revert. J Neurochem (2006) 1.34

Expression of the macrophage scavenger receptor, a multifunctional lipoprotein receptor, in microglia associated with senile plaques in Alzheimer's disease. Am J Pathol (1996) 1.31

Cell-extracellular matrix interactions stimulate the AP-1 transcription factor in an integrin-linked kinase- and glycogen synthase kinase 3-dependent manner. Mol Cell Biol (1999) 1.30

Lithium inhibits amyloid secretion in COS7 cells transfected with amyloid precursor protein C100. Neurosci Lett (2002) 1.29

Glycogen synthase kinase3 beta phosphorylates serine 33 of p53 and activates p53's transcriptional activity. BMC Cell Biol (2001) 1.26

Lithium protects cultured neurons against beta-amyloid-induced neurodegeneration. FEBS Lett (1999) 1.23

Insulin regulates soluble amyloid precursor protein release via phosphatidyl inositol 3 kinase-dependent pathway. FASEB J (2000) 1.23

Phosphorylation sites on tau by tau protein kinase I, a bovine derived kinase generating an epitope of paired helical filaments. Neurosci Lett (1992) 1.19

Increased MAP kinase activity in Alzheimer's and Down syndrome but not in schizophrenia human brain. Eur J Neurosci (2004) 1.18

GSK3: an in-Toll-erant protein kinase? Nat Immunol (2005) 1.11

Anti-inflammatory drugs in the fight against Alzheimer's disease. Ann N Y Acad Sci (1996) 1.07

Sites of phosphorylation in tau and factors affecting their regulation. Biochem Soc Symp (2001) 1.06

A beta immunotherapy: Lessons learned for potential treatment of Alzheimer's disease. Neurodegener Dis (2005) 1.04

Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci Lett (2005) 1.04

GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. Eur J Neurosci (2006) 0.97

Glycogen synthase kinase-3 regulates cytoskeleton and translocation of Rac1 in long cellular extensions of human keratinocytes. Exp Cell Res (2004) 0.95

Gene structure and alternative splicing of glycogen synthase kinase 3 beta (GSK-3beta) in neural and non-neural tissues. Gene (2003) 0.93

Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci. Am J Med Genet B Neuropsychiatr Genet (2007) 0.93

Neurofibrillary tangles and tau phosphorylation. Biochem Soc Symp (2001) 0.92

GSK-3beta reduces cAMP-induced cholecystokinin gene expression by inhibiting CREB binding. Neuroreport (2004) 0.85

Association between glycogen synthase kinase-3beta genetic polymorphism and late-onset Alzheimer's disease. Dement Geriatr Cogn Disord (2006) 0.84

Rat microglia exhibit increased density on Alzheimer's plaques in vitro. Exp Neurol (1998) 0.79

Articles by these authors

Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet (2009) 15.15

Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet (2011) 9.23

Protective variant for hippocampal atrophy identified by whole exome sequencing. Ann Neurol (2015) 5.10

Candidate single-nucleotide polymorphisms from a genomewide association study of Alzheimer disease. Arch Neurol (2007) 5.09

Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease. Arch Gen Psychiatry (2010) 3.64

Functional annotation of the human brain methylome identifies tissue-specific epigenetic variation across brain and blood. Genome Biol (2012) 3.31

The South London and Maudsley NHS Foundation Trust Biomedical Research Centre (SLAM BRC) case register: development and descriptive data. BMC Psychiatry (2009) 3.15

Evidence for novel susceptibility genes for late-onset Alzheimer's disease from a genome-wide association study of putative functional variants. Hum Mol Genet (2007) 2.73

Genetic evidence implicates the immune system and cholesterol metabolism in the aetiology of Alzheimer's disease. PLoS One (2010) 2.57

Is MCI really just early dementia? A systematic review of conversion studies. Int Psychogeriatr (2004) 2.54

The dementias. Lancet (2002) 2.42

A scan of chromosome 10 identifies a novel locus showing strong association with late-onset Alzheimer disease. Am J Hum Genet (2005) 2.04

Association of late-onset Alzheimer's disease with genetic variation in multiple members of the GAPD gene family. Proc Natl Acad Sci U S A (2004) 1.95

Alzheimer's disease-do tauists and baptists finally shake hands? Trends Neurosci (2002) 1.83

Full genome screen for Alzheimer disease: stage II analysis. Am J Med Genet (2002) 1.77

Glycogen synthase kinase-3beta and tau genes interact in Alzheimer's disease. Ann Neurol (2008) 1.74

Proteome-based plasma markers of brain amyloid-β deposition in non-demented older individuals. J Alzheimers Dis (2010) 1.73

DAPK1 variants are associated with Alzheimer's disease and allele-specific expression. Hum Mol Genet (2006) 1.73

The C9ORF72 expansion mutation is a common cause of ALS+/-FTD in Europe and has a single founder. Eur J Hum Genet (2012) 1.71

SNPs associated with cerebrospinal fluid phospho-tau levels influence rate of decline in Alzheimer's disease. PLoS Genet (2010) 1.58

Neuronal differentiation by TAp73 is mediated by microRNA-34a regulation of synaptic protein targets. Proc Natl Acad Sci U S A (2011) 1.58

Glycogen synthase kinase-3 inhibition is integral to long-term potentiation. Eur J Neurosci (2007) 1.50

SORL1 variants and risk of late-onset Alzheimer's disease. Neurobiol Dis (2007) 1.49

Evidence for a role of the rare p.A152T variant in MAPT in increasing the risk for FTD-spectrum and Alzheimer's diseases. Hum Mol Genet (2012) 1.46

Multivariate analysis of MRI data for Alzheimer's disease, mild cognitive impairment and healthy controls. Neuroimage (2010) 1.44

Schizophrenia as a GSK-3 dysregulation disorder. Trends Neurosci (2007) 1.42

The AddNeuroMed framework for multi-centre MRI assessment of Alzheimer's disease: experience from the first 24 months. Int J Geriatr Psychiatry (2011) 1.35

Automated hippocampal shape analysis predicts the onset of dementia in mild cognitive impairment. Neuroimage (2011) 1.34

Do antidepressants regulate how cortisol affects the brain? Psychoneuroendocrinology (2004) 1.32

Plasma clusterin concentration is associated with longitudinal brain atrophy in mild cognitive impairment. Neuroimage (2011) 1.30

Candidate blood proteome markers of Alzheimer's disease onset and progression: a systematic review and replication study. J Alzheimers Dis (2014) 1.29

Deletion of Irs2 reduces amyloid deposition and rescues behavioural deficits in APP transgenic mice. Biochem Biophys Res Commun (2009) 1.28

MRI measures of Alzheimer's disease and the AddNeuroMed study. Ann N Y Acad Sci (2009) 1.28

Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. Age Ageing (2003) 1.26

Biomarkers for Alzheimer's disease therapeutic trials. Prog Neurobiol (2010) 1.26

Alpha-T-catenin is expressed in human brain and interacts with the Wnt signaling pathway but is not responsible for linkage to chromosome 10 in Alzheimer's disease. Neuromolecular Med (2004) 1.26

AddNeuroMed and ADNI: similar patterns of Alzheimer's atrophy and automated MRI classification accuracy in Europe and North America. Neuroimage (2011) 1.24

Risk of developing dementia in people with diabetes and mild cognitive impairment. Br J Psychiatry (2010) 1.24

Inhibition of GSK-3 ameliorates Abeta pathology in an adult-onset Drosophila model of Alzheimer's disease. PLoS Genet (2010) 1.23

Genome screen for loci influencing age at onset and rate of decline in late onset Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2005) 1.22

Genome-wide linkage analysis of 723 affected relative pairs with late-onset Alzheimer's disease. Hum Mol Genet (2007) 1.16

Four components describe behavioral symptoms in 1,120 individuals with late-onset Alzheimer's disease. J Am Geriatr Soc (2006) 1.15

E1A activates transcription of p73 and Noxa to induce apoptosis. J Biol Chem (2004) 1.14

Effect of APOE ε4 allele on cortical thicknesses and volumes: the AddNeuroMed study. J Alzheimers Dis (2010) 1.12

Blood-based biomarkers of Alzheimer's disease: challenging but feasible. Biomark Med (2010) 1.12

Neurotoxic and neurotrophic roles of proNGF and the receptor sortilin in the adult and ageing nervous system. Eur J Neurosci (2008) 1.12

Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease. Neurobiol Aging (2013) 1.12

Mitochondrial dysfunction and immune activation are detectable in early Alzheimer's disease blood. J Alzheimers Dis (2012) 1.11

Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J Neurol (2008) 1.11

Sensitivity and specificity of medial temporal lobe visual ratings and multivariate regional MRI classification in Alzheimer's disease. PLoS One (2011) 1.10

Combination analysis of neuropsychological tests and structural MRI measures in differentiating AD, MCI and control groups--the AddNeuroMed study. Neurobiol Aging (2009) 1.09

Association of ABCA1 with late-onset Alzheimer's disease is not observed in a case-control study. Neurosci Lett (2004) 1.09

p53 is upregulated in Alzheimer's disease and induces tau phosphorylation in HEK293a cells. Neurosci Lett (2007) 1.08

Analysis of regional MRI volumes and thicknesses as predictors of conversion from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging (2010) 1.08

A comprehensive testing protocol for MRI neuroanatomical segmentation techniques: Evaluation of a novel lateral ventricle segmentation method. Neuroimage (2011) 1.06

Plasma biomarkers of brain atrophy in Alzheimer's disease. PLoS One (2011) 1.06

The importance of tau phosphorylation for neurodegenerative diseases. Front Neurol (2013) 1.05

A blood gene expression marker of early Alzheimer's disease. J Alzheimers Dis (2013) 1.05

Different multivariate techniques for automated classification of MRI data in Alzheimer's disease and mild cognitive impairment. Psychiatry Res (2013) 1.05

A feasibility and tolerability study of lithium in Alzheimer's disease. Int J Geriatr Psychiatry (2008) 1.04

Complement activation as a biomarker for Alzheimer's disease. Immunobiology (2011) 1.04

Glycogen synthase kinase-3 is increased in white cells early in Alzheimer's disease. Neurosci Lett (2005) 1.04

Evidence that common variation in NEDD9 is associated with susceptibility to late-onset Alzheimer's and Parkinson's disease. Hum Mol Genet (2007) 1.03

Alzheimer risk variant CLU and brain function during aging. Biol Psychiatry (2012) 1.02

The role of variation at AβPP, PSEN1, PSEN2, and MAPT in late onset Alzheimer's disease. J Alzheimers Dis (2012) 1.02

Identification of cis-regulatory variation influencing protein abundance levels in human plasma. Hum Mol Genet (2012) 1.02

The antidepressant clomipramine regulates cortisol intracellular concentrations and glucocorticoid receptor expression in fibroblasts and rat primary neurones. Neuropsychopharmacology (2003) 1.01

Entorhinal cortex thickness predicts cognitive decline in Alzheimer's disease. J Alzheimers Dis (2013) 1.01

APOE ε2 allele is associated with larger regional cortical thicknesses and volumes. Dement Geriatr Cogn Disord (2010) 1.00

Education increases reserve against Alzheimer's disease--evidence from structural MRI analysis. Neuroradiology (2012) 0.99

Over-expression of tau results in defective synaptic transmission in Drosophila neuromuscular junctions. Neurobiol Dis (2005) 0.99

Plasma transthyretin as a candidate marker for Alzheimer's disease. J Alzheimers Dis (2012) 0.99

Plasma based markers of [11C] PiB-PET brain amyloid burden. PLoS One (2012) 0.98

Magnetic resonance imaging and magnetic resonance spectroscopy for detection of early Alzheimer's disease. J Alzheimers Dis (2011) 0.98

GSK3alpha exhibits beta-catenin and tau directed kinase activities that are modulated by Wnt. Eur J Neurosci (2006) 0.97

Ubiquilin 1 polymorphisms are not associated with late-onset Alzheimer's disease. Ann Neurol (2006) 0.97

A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease. Electrophoresis (2009) 0.96

Diagnosing Alzheimer's disease--non-clinicians and computerised algorithms together are as accurate as the best clinical practice. Int J Geriatr Psychiatry (2007) 0.94

Specific isoforms of p73 control the induction of cell death induced by the viral proteins, E1A or apoptin. Cell Cycle (2007) 0.93

Candidate gene association study of insulin signaling genes and Alzheimer's disease: evidence for SOS2, PCK1, and PPARgamma as susceptibility loci. Am J Med Genet B Neuropsychiatr Genet (2007) 0.93

Genetic variants influencing human aging from late-onset Alzheimer's disease (LOAD) genome-wide association studies (GWAS). Neurobiol Aging (2012) 0.92

Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study. Am J Med Genet B Neuropsychiatr Genet (2005) 0.92

Plasma gelsolin is decreased and correlates with rate of decline in Alzheimer's disease. J Alzheimers Dis (2010) 0.92

Association studies between risk for late-onset Alzheimer's disease and variants in insulin degrading enzyme. Am J Med Genet B Neuropsychiatr Genet (2005) 0.92

A structural switch of presenilin 1 by glycogen synthase kinase 3beta-mediated phosphorylation regulates the interaction with beta-catenin and its nuclear signaling. J Biol Chem (2007) 0.92

OPCRIT+: an electronic system for psychiatric diagnosis and data collection in clinical and research settings. Br J Psychiatry (2011) 0.92

TAp73 isoforms antagonize Notch signalling in SH-SY5Y neuroblastomas and in primary neurones. J Neurochem (2006) 0.91

Combinatorial markers of mild cognitive impairment conversion to Alzheimer's disease--cytokines and MRI measures together predict disease progression. J Alzheimers Dis (2011) 0.91

No evidence that extended tracts of homozygosity are associated with Alzheimer's disease. Am J Med Genet B Neuropsychiatr Genet (2011) 0.91

Sequence variation in the CHAT locus shows no association with late-onset Alzheimer's disease. Hum Genet (2003) 0.91